Medtronic has announced that an independent Data Monitoring Committee (DMC) reviewed the initial interim analysis and ...

June 2 (Reuters) - Managed care company Humana Inc has filed a lawsuit against Medtronic Inc accusing the medical device maker of falsely representing its Infuse bone growth-stimulation product as ...

Infuse for TLIF initially received FDA breakthrough device designation in April 2024. A new indication could expand treatment options for spine surgery patients if approved, Medtronic says. The ...

Minneapolis-based Medtronic faces approximately 700 lawsuits involving 1,000 patients claiming personal injury due to the company's Infuse bone graft product, according to the company's SEC filing ...

Medtronic ran a retrospective study of 3,647 Infuse patients from 2006-2008 but shut it down without reporting more than 1,000 "adverse events" to the government within 30 days, as the law required.

Medtronic informed the Tribune that the company stands by Infuse. In his letter to Mr. Franken, Mr. King provided details into the study’s numbers.

NEW YORK, N.Y. - Medtronic Inc. is funding two independent reviews of studies of its Infuse bone graft in the wake of criticism of the clinical trials it conducted to support the device.

Medtronic's pledge of an independent review "appears to be a step in the right direction," said Dr. Carragee, who is also editor-in-chief of Spine, in a statement.

A U.S. Appeals Court rejected a patient's effort to sue Medtronic for an "off-label" use of the bone-growth product. Hundreds of others are in the same situation.

A U.S. advisory panel voted on Thursday to recommend that Medtronic Inc.'s <MDT.N> Infuse be conditionally approved as safe and effective for oral bone grafting procedures.